Aspira Women's Health Inc.
Index- P/E- EPS (ttm)-0.28 Insider Own0.50% Shs Outstand117.12M Perf Week-10.39%
Market Cap39.50M Forward P/E- EPS next Y-0.24 Insider Trans0.00% Shs Float69.04M Perf Month-16.88%
Income-31.00M PEG- EPS next Q-0.07 Inst Own14.70% Short Float / Ratio2.18% / 4.85 Perf Quarter-39.68%
Sales7.90M P/S5.00 EPS this Y-60.20% Inst Trans3.82% Short Interest1.51M Perf Half Y-41.96%
Book/sh0.10 P/B3.20 EPS next Y17.20% ROA-103.50% Target Price3.00 Perf Year-84.08%
Cash/sh0.17 P/C1.92 EPS next 5Y- ROE-160.70% 52W Range0.32 - 2.26 Perf YTD-81.92%
Dividend- P/FCF- EPS past 5Y0.10% ROI-96.20% 52W High-85.83% Beta2.75
Dividend %- Quick Ratio3.10 Sales past 5Y20.90% Gross Margin52.00% 52W Low0.00% ATR0.03
Employees106 Current Ratio3.10 Sales Q/Q23.50% Oper. Margin- RSI (14)30.54 Volatility10.54% 9.27%
OptionableYes Debt/Eq0.24 EPS Q/Q55.10% Profit Margin- Rel Volume2.84 Prev Close0.35
ShortableYes LT Debt/Eq0.21 EarningsNov 10 BMO Payout- Avg Volume310.45K Price0.32
Recom2.50 SMA20-15.92% SMA50-17.52% SMA200-54.08% Volume883,538 Change-8.57%
Jan-12-22Resumed Cantor Fitzgerald Overweight $4
Mar-29-21Initiated Truist Buy $12
Jan-29-21Initiated Cantor Fitzgerald Overweight $10
Oct-30-20Initiated William Blair Outperform
Nov-10-22 07:00AM
Nov-01-22 08:00AM
Oct-06-22 04:05PM
Oct-05-22 08:00AM
Sep-27-22 09:05AM
04:28PM Loading…
Sep-12-22 04:28PM
Aug-23-22 08:00AM
Aug-22-22 04:02PM
Aug-18-22 04:05PM
Aug-10-22 07:30AM
Aug-01-22 08:00AM
Jul-11-22 06:26AM
Jun-23-22 04:05PM
Jun-16-22 04:01PM
May-18-22 07:31AM
01:20PM Loading…
May-16-22 01:20PM
May-12-22 04:01PM
May-11-22 07:30AM
Apr-29-22 08:00AM
Apr-02-22 01:40PM
Mar-23-22 07:00AM
Mar-15-22 08:00AM
Feb-28-22 08:14AM
Feb-24-22 04:01PM
Feb-22-22 04:05PM
Feb-08-22 01:46PM
Feb-01-22 04:19AM
Jan-31-22 04:05PM
Jan-28-22 10:07AM
Jan-05-22 08:00AM
08:00AM Loading…
Dec-03-21 04:57AM
Nov-10-21 08:00AM
Nov-03-21 03:01PM
Nov-01-21 08:00AM
Oct-19-21 06:52AM
Oct-07-21 08:00AM
Sep-30-21 08:00AM
Sep-29-21 08:00AM
Sep-21-21 08:00AM
Sep-09-21 08:00AM
Sep-04-21 08:30AM
Aug-12-21 04:05PM
Aug-05-21 03:00PM
Jul-27-21 04:01PM
Jul-21-21 01:46AM
Jul-15-21 06:17AM
Jul-08-21 08:57AM
Jun-15-21 03:54AM
Jun-03-21 08:00AM
May-27-21 07:15PM
May-19-21 08:00AM
May-15-21 03:24AM
May-13-21 02:30PM
May-12-21 04:05PM
May-11-21 04:05PM
May-06-21 03:00PM
May-05-21 08:00AM
Mar-30-21 02:00AM
Mar-26-21 09:38AM
Mar-25-21 04:20PM
Mar-18-21 12:30PM
Mar-15-21 08:00AM
Feb-22-21 08:30AM
Feb-17-21 08:00AM
Feb-12-21 04:18PM
Feb-10-21 05:38PM
Feb-04-21 09:25AM
Feb-03-21 04:03PM
Jan-28-21 08:00AM
Jan-04-21 04:34PM
Dec-20-20 01:27AM
Nov-29-20 08:24PM
Nov-19-20 08:00AM
Nov-14-20 07:24AM
Nov-12-20 04:01PM
Nov-10-20 08:30AM
Nov-09-20 08:00AM
Nov-05-20 08:00AM
Nov-04-20 08:00AM
Oct-28-20 08:00AM
Oct-14-20 08:00AM
Oct-09-20 08:00AM
Oct-08-20 03:30PM
Oct-06-20 07:57AM
Sep-28-20 08:30AM
Sep-15-20 05:01PM
Sep-08-20 11:44AM
Aug-22-20 10:01AM
Aug-14-20 03:51PM
Aug-13-20 04:01PM
Jul-31-20 09:23AM
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Palmieri Valerie BarberExecutive ChairMay 16Buy0.5743,99424,918267,088May 18 09:22 AM
Sandford NicolePresident and CEOMay 16Buy0.7698,00074,892136,160May 17 05:02 PM